ERBB2 and breast cancer: Gallen Consensus Meeting suggested that the Ki67 LI is important for distinguishing between ‘‘luminal A” and ‘‘luminal B (HER2-negative)” breast cancer subtypes and advised adjuvant chemotherapy for luminal B but not for luminal A [8].